An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine the maximum safe dose of a drug called MLN0128.
Description
The purpose of this study is to determine the maximum safe dose of a drug called MLN0128.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
liver cancer,hepatocellular carcinoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1510568400
